Back to search

Aristotle University Of Thessaloniki (AUTH)

Η επίδραση της λεβοσιμεντάνης στη λειτουργικότητα της αριστερής κοιλίας στα οξέα στεφανιαία σύνδρομα

Abstract

dc:description

Aim. To evaluate left ventricular function based on biochemical parameters after administration of levosimendan in patients with acute coronary syndromes (ACS).Material and Methods. The study population, consisted of 46 patients with ACS, were randomly distributed into 2 groups, A and B. In group A (31 patients) levosimendan was administered for 24 hours at maximum tolerated dose whilst B group (15 patients), was the control group. Biomarkers such IL-6, IL-10, V-CAM-1, hs-CRP, BNP and troponin I were measured among admission and discharge. Mortality rate and drug side effects were also reported. P <0.05 was considered statistically significant.Results. 30/46 patients were males aged 70 years (min 44, max 85 years) and 16/46 females aged 69.54 ± 11.04 years, staying at hospital about 7 days. Ηalf patients were STEMI and half ones were NSTEMI. No aggravation of liver and renal function in group A was observed. In group A, IL6 was higher at discharge when compared to admission (4.29 ± 0.85 vs 4.8, min 3.9 and max 8.8, p <0.05), IL10 was also higher (7.28 ± 1.97 vs 8.7 ± 3.6, p> 0.05). TNFa was lower at discharge compared to admission (22.4 ± 4.91 vs 17.4 ± 8.29, p> 0.05) and so was CRP (0.6, min 0.08 and max 1.8 vs 0.49 ± 0.33, p> 0.05), while VCAM-1 and BNP were increased (4.8, min 3.2, max 10 & 68, min 5, max 630 at admission vs 6.01 ± 2.35 & 106, min 6.2, max 927 at discharge, respectively, p> 0.05). Moreover, in STEMI patients with initial BNP values <100 pg/ml, BNP retained normal (21.9, min 5 max 89.3, at admission vs 56.45, min 6.20 max 927, at discharge, respectively, p=0.04<0.05). Troponin was decreased at discharge compared to admission (1.27, min 0.01, max> 10 vs 0.66, min 0.01, max 7.66, p <0.05). In group B, IL6 was higher at discharge (4.04 ± 0.56 vs 5.6 ± 1.95, p <0.05) while IL10 was lower, respectively (7.27 ± 2.9 vs 4.2, min 2,8 and max 18, p > 0.05), as well as TNF-a (24.07 ± 0.82 vs 20.39 ± 8.48, p> 0.05) and CRP (0.8, min 0.08 and max 0.9 vs 0.58 ± 0.29 respectively, p> 0.05). VCAM-1 and BNP were increased (5.26 ± 2.09 & 89.4, min 5, max 580 at admission vs 7.08 ± 2.36 & 149, min 5, max 904 at discharge, respectively, p> 0.05). Troponin was decreased at discharge compared to admission (1.8, min 0.03, max> 10 vs 0.79 ± 0.73, respectively, p <0.05). The drug was well tolerated by patients in group A, no mortality rate was observed and few incidents of hypotension were reported.Conclusions. The administration of levosimendan does not seem to improve left ventricular function in patients with ACS based on the above identified biomarkers. Moreover, it seems that the drug has a positive impact on left ventricular function mainly in STEMI patients with initial normal BNP values. The significant decrease of troponin I during hospital discharge compared to admission in both two groups apparently reflects the natural evolution of the disease. Generally, levosimendan is a well-tolerated drug that did not impair kidney and liver function causing hypotension rarely.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bostanitis, Ioannis
  • Μποστανίτης, Ιωάννης

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/34682

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bostanitis, Ioannis; Μποστανίτης, Ιωάννης. Η επίδραση της λεβοσιμεντάνης στη λειτουργικότητα της αριστερής κοιλίας στα οξέα στεφανιαία σύνδρομα. Aristotle University Of Thessaloniki (AUTH), 2014. http://hdl.handle.net/10442/hedi/34682